Since luminal A breast cancers that are CREB3L1-deficient also show a poor prognosis as compared to those expressing CREB3L112, we extended this analysis to determine the drug sensitivity in several luminal A breast cancer cell lines, some of which were also tested with re-expressed CREB3L1 (Table 2). This evidence concerns the gene CREB3L1 and breast carcinoma.